De-identified Health Data Market, Share & Trends Analysis Report, By Type of Data (Clinical, Genomic and Others), By End-use (Pharmaceutical Companies, Biotechnology Firms and Others), By Application, By Region, and Segment Forecasts, 2023-2031

The De-identified Health Data Market Size is valued at USD 7.29 Bn in 2023 and is predicted to reach USD 13.77 Bn by the year 2031 at an 8.5% CAGR during the forecast period for 2024-2031.

De-identification is an organizational method used to eliminate personal information from data that is gathered, utilized, stored, and shared with other organizations. Rather than being a single strategy, it encompasses a set of approaches, algorithms, and tools applied to various types of data with differing levels of effectiveness. More aggressive de-identification algorithms typically provide stronger privacy protection, though they can reduce the dataset's overall usefulness. For enterprises, government agencies, and other organizations that seek to make data accessible to external parties, de-identification is especially crucial. It safeguards individuals' privacy by preventing the unauthorized disclosure of their personal health information. This allows de-identified data to be used for diverse research purposes without compromising patient confidentiality and facilitates the sharing of health data for collaborative research and analysis.

Section 164.514(a) of the HIPAA Privacy Rule provides the standard for de-identification of protected health information, stating that health information is not considered individually identifiable if it does not identify an individual and if the covered entity has no reasonable basis to believe it could be used to identify one. Similarly, the General Data Protection Regulation (GDPR) in the European Union sets strict standards for data protection, including the processing of personal data, which can include de-identified health data. Both regulatory frameworks, HIPAA and GDPR, impose stringent requirements for managing personal health information. De-identification serves as a key method for organizations to comply with these regulations while still making health data available for research and collaboration. As healthcare systems become increasingly interconnected, the need for collaboration between institutions, researchers, and pharmaceutical companies grows. De-identified data facilitates the exchange of health information across organizations, supporting joint research, drug development, and clinical trials without compromising patient confidentiality.

Competitive Landscape

Some of the Major Key Players in the De-identified Health Data Market are

• IQVIA
• Oracle
• Merative
• Optum, Inc.
• ICON plc
• Veradigm LLC
• IBM
• Flatiron Health
• Premier, Inc.
• Shaip
• Komodo Health, Inc.
• Evidation Health, Inc.
• Medidata
• Clarify Health Solutions
• Satori Cyber Ltd.
• Kitware
• BioData Consortium
• Akrivia Health
• iMerit

Market Segmentation

The de-identified health data market is segmented based on the type of data, end-use, application. Based on the type of data, the market is divided into clinical, genomic, patient demographics, prescription data, claims data, behavioral data, wearable and sensor data, survey and patient-reported data, imaging data, laboratory data, hospital and provider data, social determinants of health (SDOH) data, pharmacogenomic data, biometric data, operational and financial data, epidemiological data, healthcare utilization data, others. Based on the end-use, the market is divided pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, insurance companies/ healthcare payers, research institutions, government agencies and others. Based on the application, the market is divided into clinical research and trials, public health, precision medicine, health economics and outcomes research (HEOR), population health management, drug discovery and development, healthcare quality improvement, insurance underwriting and risk assessment, market access and commercial strategy, business intelligence and operational efficiency, telemedicine and remote monitoring, patient engagement and support programs, others.

The Clinical Data Segment is Expected to Have the Highest Growth Rate During the Forecast Period

Based on the type of data, the market is divided into clinical, genomic, patient demographics prescription data, claims data, behavioral data, wearable and sensor data, survey and patient-reported data, imaging data, laboratory data, hospital and provider data, social determinants of health (SDOH) data, pharmacogenomic data, biometric data, operational and financial data, epidemiological data, healthcare utilization data, others. Among these, the clinical data segment is expected to have the highest growth rate during the forecast period. Clinical data includes a wide range of information such as medical histories, diagnoses, treatments, procedures, outcomes, and lab results. This data provides a detailed view of patient health, making it highly valuable for research, healthcare optimization, and decision-making. Clinical data is essential for advanced healthcare analytics, machine learning, and AI-driven models aimed at improving diagnostics, predicting health outcomes, and optimizing healthcare delivery. The use of this data fuels advancements in personalized medicine and value-based care.

The Clinical Research and Trials Segment Dominates the Market

Based on the application, the market is divided into clinical research and trials, public health, precision medicine, health economics and outcomes research (HEOR), population health management, drug discovery and development, healthcare quality improvement, insurance underwriting and risk assessment, market access and commercial strategy, business intelligence and operational efficiency, telemedicine and remote monitoring, patient engagement and support programs, others. Among these, the clinical research and trials segment dominates the market. Clinical research and trials require access to vast amounts of health data to generate statistically significant results. De-identified health data provides researchers with large, diverse patient datasets while protecting individual privacy. This is essential for understanding disease progression, treatment effectiveness, and potential side effects across different populations. Pharmaceutical and biotech companies are major consumers of de-identified health data, as they are constantly conducting research for drug discovery and clinical trials. The continuous demand for de-identified data by these industries ensures that the clinical research and trials segment remains dominant.

North America has the Largest Market Share During the Forecast Period.

North America leads in the development and adoption of advanced healthcare analytics, machine learning, and AI technologies. These innovations require large volumes of health data to train algorithms and develop predictive models. De-identified health data is critical to feeding these technologies, driving further demand in the region. The rise of precision medicine in North America, especially through initiatives like the All of Us Research Program in the U.S., requires vast amounts of diverse and de-identified health data to understand genetic, environmental, and lifestyle factors that influence health. North America's leadership in precision medicine drives the demand for de-identified datasets to enable tailored treatments and interventions.

Recent Developments:

• In December 2020, DeNA Life Science Inc and IQVIA collaboration on the Genome Wide Study Platform, a platform for pharmaceutical companies, in December 2020 with the goal of building a database of statistical genetic information* about disease and pertinent analysis findings of survey data on disease, physical predispositions, lifestyle choices, etc., and using that data for drug utility & safety validation and drug discovery research.

• In Oct 2018, IQVIA, declared that it will collaborate with Genomics England to create a platform that combines clinical and de-identified genomics data; the nature of the partnership was not disclosed.

De-identified Health Data Market Report Scope

Segmentation of De-identified Health Data Market

Global De-identified Health Data Market- By End Use

• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Healthcare Providers
• Insurance Companies/ Healthcare Payers
• Research Institutions
• Government Agencies
• Others

Global De-identified Health Data Market – By Application

• Clinical Research and Trials
• Public Health
• Precision Medicine
• Health Economics and Outcomes Research (HEOR)
• Population Health Management
• Drug Discovery and Development
• Healthcare Quality Improvement
• Insurance Underwriting and Risk Assessment
• Market Access and Commercial Strategy
• Business Intelligence and Operational Efficiency
• Telemedicine and Remote Monitoring
• Patient Engagement and Support Programs
• Others

Global De-identified Health Data Market – Type of Data

• Clinical Data
• Genomic Data
• Patient Demographics
• Prescription Data
• Claims Data
• Behavioral Data
• Wearable and Sensor Data
• Survey and Patient-Reported Data
• Imaging Data
• Laboratory Data
• Hospital and Provider Data
• Social Determinants of Health (SDoH) Data
• Pharmacogenomic Data
• Biometric Data
• Operational and Financial Data
• Epidemiological Data
• Healthcare Utilization Data
• Others

 Global De-identified Health Data Market – By Region

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East